Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 10 of about 11   

Articles published

DVAX 21.74
price chart
Analysts At William Blair Maintain Outperform On Dynavax Technologies
The firm points out that Dynavax has received the briefing book from the FDA by now and no news so far is good news. Moreover, Dynavax had communicated that if there were material information, the company would disclose it to the public. The firm ...
The Fall Of Another Promising Biotech - Dynavax Technologies
Dynavax Technologies Corp. (NASDAQ:DVAX) announced Thursday that an FDA advisory committee voted overwhelmingly in favor (13-1) of the company's hepatitis B vaccine Heplisav in terms of efficacy, saying the drug clearly showed immunogenicity in ...
Dynavax Falls After Vaccine Fails to Win Panel Backing  Bloomberg
Dynavax Shares Jump On Release Of FDA Briefing Materials
As I wrote earlier, Dynavax Technologies Corporation (NASDAQ:DVAX) announced on April 28, 2012, it had submitted a U.S. Biologics License Application, or BLA, to the FDA for HEPLISAV, its treatment for hepatitis B. The company is pursuing an indication ...
Dynavax's Heplisav Vaccine Works on Hepatitis B, FDA Says  Bloomberg
Despite Safety Concerns, Dynavax's Heplisav Should Receive FDA Approval
Dynavax is a clinical-stage biopharmaceutical company developing preventative and curative treatments for infectious and inflammatory diseases.
Dynavax Upcoming Binary Event: HBV Vaccine Under Review By FDA Advisory ...
Dynavax Technologies Corporation (NASDAQ:DVAX) is a small biotech company with an upcoming binary event on its stock. The FDA advisory committee will meet on November 15, 201,2 to discuss the company's HBV vaccine.
Why Dynavax's HEPLISAV Is Likely To Be Approved: Impact On Future Vaccine ...
Dynavax's (NASDAQ:DVAX) HEPLISAV had an FDA Advisory Committee on November 15, 2012. The Advisory Committee voted 13 to one that HEPLISAV data adequately demonstrated immunogenicity.
Pre-Market Movers (Green Mountain, Knight Capital, Costco, Freeport-McMoRan ...
Dynavax Technologies Corp. (DVAX) stock tumbled 16.52 percent to $2.35 in pre-market trading. The stock has a 52-week low of $2.22, a 52-week high of $5.34 and $503.06 million in market capitalization.
U.S. Stock Futures Retreat as Obama Holds Budget Talks
Dynavax Technologies Corp. tumbled 47 percent to $2.44 after its hepatitis B vaccine Heplisav failed to win the backing of U.S.
Stocks to Watch: Schiff Nutrition, Penn National Gaming, Gap
Shares rose 4.3% premarket to $34.70, as the company also raised its full-year earnings view. Shares of Dynavax Technologies Corp. (DVAX) plunged 53% to $2.15 after a surprise FDA advisory-panel decision that could hold up approval of its hepatitis C ...
JA Solar Has to Stoop to a Reverse Stock Split
What you are about to read is a sneaky way of announcing a reverse stock split to stay within the listing standards of the $1.00 share price rule.